Oncology Corporate Profile
10.8650 | |
-0.1400 |
Sorrento is an oncology company developing new treatments for cancer and its associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, commenced its registrational trial on March 31, 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opioid TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain.
Website: http://sorrentotherapeutics.com
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
cynviloq | monoclonal antibody | Breast Cancer | III | |
cynviloq | monoclonal antibody | Non Small Cell Lung Cancer (NSCLC) | III | |
cynviloq | monoclonal antibody | Bladder cancer | II | |
cynviloq | monoclonal antibody | Ovarian cancer | II | |
cynviloq | monoclonal antibody | Pancreatic Cancer | II |
View additional information on product candidates here »